ZEPHYR Trial Testing Livoletide for Hyperphagia Still Recruiting Children Ages 4-7
Livoletide, a potential therapy to curb excessive eating among people with Prader-Willi syndrome (PWS), is being tested in a global Phase 2b/3 clinical trial called ZEPHYR. Although recruitment of participants ages 8-65 has been completed, enrollment of children ages 4-7 is still ongoing. To date, 4 children…